Physician profile
Christopher Caputo
NPI 1992703490
$7,264.27
in general payments reported to CMS, 2019-2025
33 companies · $892 in 2025
The $892 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,582 · 2020: $443 · 2021: $807 · 2022: $1,053 · 2023: $1,346 · 2024: $1,141 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,265 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,265.09 |
| Education | $113.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $794.38 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Astrazeneca Pharmaceuticals Lp | $673.17 | 2019-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $640.00 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $637.19 | 2019-2024 | Velphoro |
| Opko Pharmaceuticals, LLC | $531.53 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $522.04 | 2021-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $478.78 | 2019-2024 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $421.22 | 2020-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $403.38 | 2019-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $375.93 | 2019-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $338.73 | 2021-2025 | |
| Horizon Therapeutics Plc | $317.01 | 2019-2022 | |
| Ardelyx, INC. | $201.58 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Glaxosmithkline, LLC. | $151.16 | 2021-2024 | Benlysta, Jesduvroq |
| Calliditas Therapeutics US INC. | $138.60 | 2023-2024 | Tarpeyo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $113.25 | 2024-2025 | |
| Mallinckrodt Enterprises LLC | $74.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.34 | 2022-2024 | Gattex |
| Neurocrine Biosciences, INC. | $57.02 | 2025 | |
| Bard Peripheral Vascular, INC. | $45.21 | 2019 | |
| Ani Pharmaceuticals, INC. | $37.34 | 2022-2023 | Purified Cortrophin Gel |
| Grifols USA, LLC | $36.76 | 2025 | Gamunex-C |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.05 | 2025 | Voyxact |
| Renalytix Ai, INC. | $22.81 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Boston Scientific Corporation | $22.76 | 2025 | Ams 700 |
| Aurinia Pharma U.S., INC. | $20.91 | 2023 | Lupkynis |
| Neurelis, INC. | $19.29 | 2025 | Valtoco |
| Shield Therapeutics INC | $17.55 | 2025 | |
| Eisai INC. | $17.34 | 2025 | |
| Shire North American Group INC | $17.25 | 2019 | |
| 180 Medical, INC. | $16.26 | 2025 | Gentlecath |
| Millicent US INC | $15.77 | 2025 | Femlyv |
| Daiichi Sankyo INC. | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Caputo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.